The FDA has approved Vertex Pharmaceuticals and CRISPR Therapeutics' Casgevy to treat beta-thalassemia, Vertex said Tuesday, making it the first-ever CRISPR-edited therapy for the rare genetic blood disorder. In December, the agency OK'd Casgevy to treat seve…